Background: Optimal treatment for locally advanced cervical cancer is still a controversial issue as the current standard therapy is associated with radiation toxicity. Neo-adjuvant chemotherapy followed by surgery is an alternative treatment modality which has promising outcomes.
Cases: Two cases of cervical carcinoma, aged 33 and 40 years old, stage 1b2 and 1b3, given neoadjuvant chemotherapy (NACT) with combination of platinum-based agents and Taxane, and planned for radical surgery after completion of chemotherapy.
Result: Progression of disease observed in both cases after 3rd cycle of chemotherapy required change of treatment modalities to standard chemoradiation therapy (CCRT).
Conclusion: NACT followed by surgery has promising outcomes as it gives advantages in lower long-term complication, targeted in younger-aged group and sexually active women for better quality of life, besides offering similar survival rates compared with CCRT. Estimation of response rate to chemotherapy plays a major role in patient selection in order to have successful outcomes.
Arbyn M, Weiderpass E, Bruni L, de Sanjosé S, Saraiya M, Ferlay J, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. The Lancet Global Health. 2020; 8(2): e191-203.
Quinn MA, Benedet JL, Odicino F, Maisonneuve P, Beller U, Creasman WT, et al. Carcinoma of the cervix uteri. International Journal of Gynecology & Obstetrics. 2006; 95: S43-103.
Morris M, Eifel PJ, Lu J, Grigsby PW, Levenback C, Stevens RE, et. al. Pelvic radiation with concurrent chemotherapy compared with pelvic and paraaortic for high risk cervical cancer. N Engl Med. 1999: 340(15): 1137-43.
Lapresa M, Parma G, Portuesi R, Colombo N. Neoadjuvant chemotherapy in cervical cancer: an update. Expert Review of Anticancer Therapy. 2015; 15(10): 1171-81.
Roszak A, Wareńczak-Florczak Ż, Bratos K, Milecki P. Incidence of radiation toxicity in cervical cancer and endometrial cancer patients treated with radiotherapy alone versus adjuvant radiotherapy. Reports of Practical Oncology and Radiotherapy. 2012; 17(6): 332-8.
Paladini D, Raspagliesi F, Fontanelli R, Ntousias V. Radical surgery after induction chemotherapy in locally advanced cervical cancer. A feasibility study. International Journal of Gynecological Cancer. 1995; 5(4): 296-300.
Yang S, Gao Y, Sun J, Xia B, Liu T, Zhang H, et al. Neoadjuvant chemotherapy followed by radical surgery as an alternative treatment to concurrent chemoradiotherapy for young premenopausal patients with FIGO stage IIB squamous cervical carcinoma. Tumor Biology. 2015; 36(6): 4349-56.
Hsieh HY, Huang JW, Lu CH, Lin JC, Wang L. Definite chemoradiotherapy is a competent treatment option in FIGO stage IB2 cervical cancer compared with radical surgery+/− neoadjuvant chemotherapy. Journal of the Formosan Medical Association. 2019; 118(1): 99-108.
Gupta S, Maheshwari A, Parab P, Mahantshetty U, Hawaldar R, Sastri S, et al. Neoadjuvant chemotherapy followed by radical surgery versus concomitant chemotherapy and radiotherapy in patients with stage IB2, IIA, or IIB squamous cervical cancer: a randomized controlled trial. Journal of Clinical Oncology. 2018; 36(16): 1548-55.
Lee DW, Lee KH, Lee JW, Park ST, Park JS, Lee HN. Is neoadjuvant chemotherapy followed by radical surgery more effective than radiation therapy for stage IIB cervical cancer?. International Journal of Gynecologic Cancer. 2013; 23(7).
Zou W, Han Y, Zhang Y, Hu C, Feng Y, Zhang H, et al. Neoadjuvant chemotherapy plus surgery versus concurrent chemoradiotherapy in stage IB2-IIB cervical cancer: A systematic review and meta-analysis. PloS One. 2019; 14(11): e0225264.
Kenter G, Greggi S, Vergote I, Katsaros D, Kobierski J, Massuger L, et al. Results from neoadjuvant chemotherapy followed by surgery compared to chemoradiation for stage Ib2-IIb cervical cancer. EORTC. 55994.
Scatchard K, Forrest JL, Flubacher M, Cornes P, Williams C. Chemotherapy for metastatic and recurrent cervical cancer. Cochrane Database of Systematic Reviews. 2012(10).
Moore DH. Neoadjuvant chemotherapy for cervical cancer. Expert Opin Pharmac. 2003; 4: 859–67.
Moore DH, Tian C, Monk BJ, Long HJ, Omura GA, Bloss JD. Prognostic factors for response to cisplatin-based chemotherapy in advanced cervical carcinoma: a Gynecologic Oncology Group Study. Gynecologic Oncology. 2010; 116(1): 44-9.
Ramey SJ, Asher D, Kwon D, Ahmed AA, Wolfson AH, Yechieli R, et al. Delays in definitive cervical cancer treatment: an analysis of disparities and overall survival impact. Gynecologic Oncology. 2018; 149(1): 53-62.
Kim TE, Park BJ, Kwack HS, Kwon JY, Kim JH, Yoon SC. Outcomes and prognostic factors of cervical cancer after concurrent chemoradiation. Journal of Obstetrics and Gynaecology Research. 2012; 38(11): 1315-20.
Jung EJ, Byun JM, Kim YN, Lee KB, Sung MS, Kim KT, Jeong DH. Cervical adenocarcinoma has a poorer prognosis and a higher propensity for distant recurrence than squamous cell carcinoma. International Journal of Gynecologic Cancer. 2017; 27(6).
This work is licensed under a Creative Commons Attribution 4.0 International License.